Status:
COMPLETED
Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia
Lead Sponsor:
Coordinación de Investigación en Salud, Mexico
Collaborating Sponsors:
Instituto Mexicano del Seguro Social
University of Guadalajara
Conditions:
Conjunctival Intraepithelial Neoplasia
Corneal Intraepithelial Neoplasia
Eligibility:
All Genders
18-90 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate the therapeutic efficacy of interferon alfa 2b and topical mitomycin C in patients with diagnosis of conjunctival-corneal intraepithelial neoplasia.
Detailed Description
The corneal and conjunctival intraepithelial neoplasia is the most common malignant tumor of the ocular surface. Classic treatment is complete excision with safety margins, however, usually the edges ...
Eligibility Criteria
Inclusion
- Patients with clinical diagnosis of corneal and conjunctival intraepithelial neoplasia (CIN) with no history of ocular neoplasia
Exclusion
- Patients who did not agree to participate in the study.
- Patients with corneal abrasion
- Patients who have the diagnosis of CIN, but are pregnant
Key Trial Info
Start Date :
May 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2017
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT02199327
Start Date
May 1 2014
End Date
July 1 2017
Last Update
August 8 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IMSS Centro Médico de Occidente
Guadalajara, Jalisco, Mexico